Optimistic About Cancer Immunotherapy, Downbeat About Costs
While cancer experts are almost giddy with enthusiasm about rapid advances in cancer immunotherapy—in a field not known for euphoria--they are equally pessimistic about market access hurdles as impediments to improved patient care and are seeking manageable approaches to assessing value.
You may also be interested in...
More than a dozen new molecular entities launched for the treatment of cancer in 2012, advancing care for seriously ill people, but many carry price tags of $100,000 per year or more for treatment, escalating debate over cost of care and how best to direct limited healthcare resources.
Sanofi’s recent reduction of the Zaltrap price after the Memorial Sloan-Kettering Cancer Center said it would not provide the drug to its advanced colorectal cancer patients due to its high cost relative to Avastin highlights the role cost and available clinical evidence will have as payers make value-based purchasing decisions.
ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?